Actively Recruiting
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Led by Hansoh BioMedical R&D Company · Updated on 2025-12-17
468
Participants Needed
1
Research Sites
207 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
CONDITIONS
Official Title
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary participation and written informed consent.
- Female, 18 years and older.
- Pathologically confirmed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
- Disease must be platinum-resistant.
- Ability to provide fresh or archived tumor tissue.
- At least one measurable lesion according to RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Life expectancy greater than 12 weeks.
- Adequate bone marrow reserve and organ function.
- Use of contraception during the trial.
You will not qualify if you...
- Prior treatment with TOP1 inhibitors or antibody-drug conjugates containing TOP1 inhibitors.
- Previous or concurrent malignancies other than the study cancer.
- Uncontrolled pleural, pericardial, or abdominal effusions requiring intervention.
- Systemic anticancer treatment within 4 weeks before starting study treatment.
- Unresolved toxicities of grade 2 or higher from prior anticancer therapy.
- History of severe allergic reactions to HS-20089 or its ingredients.
- Any serious or uncontrolled medical condition that increases risk during the study.
- Other situations deemed inappropriate by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
Actively Recruiting
Research Team
L
Lingying Wu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here